PharmaTher Holdings Ltd. announced the appointment of Professor Ryan Donnelly, a world leader in the research and development of microneedle delivery technologies, as scientific and technical advisor for PharmaTher's microneedle patch delivery programs involving controlled-substances such as ketamine and compounds treating infectious diseases. Professor Donnelly currently leads the Company's research program to develop a patented hydrogel-forming microneedle patch to deliver ketamine and KETABETTM, a patented ketamine formulation, which represents a potential next-generation treatment for neuropsychiatric, neurodegenerative and pain disorders.